These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21031566)

  • 1. NerveCenter: Unintended effects of biologic drug market protection.
    Stone K
    Ann Neurol; 2010 Nov; 68(5):A11-2. PubMed ID: 21031566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
    Levi EL
    Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing innovation, access, and profits--market exclusivity for biologics.
    Engelberg AB; Kesselheim AS; Avorn J
    N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 5. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighing the outcomes.
    Russo MJ; Balekdjian D
    Nat Biotechnol; 2008 Feb; 26(2):173-82. PubMed ID: 18259169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Drug Formulations - Unintended Consequences of Legislation.
    Probst LA; Welch TR
    N Engl J Med; 2017 Feb; 376(8):795-796. PubMed ID: 28225679
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug shortage crisis resolution.
    Duffy E
    J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
    [No Abstract]   [Full Text] [Related]  

  • 9. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 10. New rules for US drug reimbursement.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 12. [Reference prices].
    Rey Abella ME
    Aten Primaria; 1999 Sep; 24(5):252-4. PubMed ID: 10590555
    [No Abstract]   [Full Text] [Related]  

  • 13. Coding and medicare payment for discarded drugs and biologicals.
    Schaum KD
    Adv Skin Wound Care; 2010 Sep; 23(9):398-403. PubMed ID: 20729644
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development costs, regulation and audit in the German SHI Drug Sector].
    Kamp F; Walter P; Bücheler R
    Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
    [No Abstract]   [Full Text] [Related]  

  • 15. Market exclusivity for biologics.
    Wheadon DE
    N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
    [No Abstract]   [Full Text] [Related]  

  • 16. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO must defend patients' interests, not industry.
    Cawthorne P; Ford N; Limpananont J; Tienudom N; Purahong W
    Lancet; 2007 Mar; 369(9566):974-5. PubMed ID: 17382809
    [No Abstract]   [Full Text] [Related]  

  • 19. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.